FiercePharma17h
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
Hosted on MSN11h
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...
BioWorld8h
CMS’ price negotiations take two: Ozempic, Xtandi among 15 drugs chosen
In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...
BioWorld15h
Huntington’s neurodegeneration starts at 150 repeat expansions
Having 35 copies of the CAG triplet in the gene that causes Huntington’s disease is not a problem. Inheriting 40 could be a ...
AbbVie price target lowered to $212 from $221 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...